CAMBRIDGE, MA / ACCESS Newswire / May 12, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked no. 1 on TIME's 2026 list of the World's Most Impactful Companies. The recognition highlights ...
Shares of Moderna (NASDAQ:MRNA) are up roughly 6% in Monday morning trading, changing hands near $57.52 after Friday’s close ...
A localized outbreak, even a fatal one, is unlikely to spark the multibillion-dollar revenue catalyst that Moderna needs.
Moderna's mRNA-based seasonal flu vaccine worked better than conventional flu shots in a late-stage international trial of ...
An mRNA-based flu shot could make a huge difference in flu prevention, allowing scientists to pick a better strain match.
Moderna stock rose 8% in premarket on Monday, extending its 12% rally on Friday. What’s behind the move: The biotech is researching vaccines to protect against ha ...
Regulatory filings are under review in the U.S., Europe, Canada and Australia, with potential approvals expected to ...
The biotech company has a pre-clinical program with the U.S. Army and a vaccine center at a Korean university. An American citizen on Sunday takes photos on his phone after he was evacuated from the ...
These efforts are early-stage and ongoing and reflect Moderna’s broader responsibility to develop countermeasures against ...
Reports first quarter revenue of $0.4 billion, with approximately 80% of revenue from international marketsReports ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results